Jens Juul Holst

Jens Juul Holst

Professor


  1. Published

    The effects of variations in dose and method of administration on glucagon like peptide-2 activity in the rat

    Kaji, T., Tanaka, H., Holst, Jens Juul, Redstone, H., Wallace, L., Heuval, E. D. & Sigalet, D. L., 2008, In: European Journal of Pharmacology. 596, 1-3, p. 138-145 7 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Published

    The effects of variations in dose and method of administration on glucagon like peptide-2 activity in the rat

    Kaji, T., Tanaka, H., Holst, Jens Juul, Redstone, H., Wallace, L., de Heuval, E. & Sigalet, D. L., 31 Oct 2008, In: European Journal of Pharmacology. 596, 1-3, p. 138-45 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Published

    The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects.

    Vilsbøll, Tina, Agersø, H., Lauritsen, T., Deacon, Carolyn F., Aaboe, K., Madsbad, Sten, Krarup, T. & Holst, Jens Juul, 2006, In: Regulatory Peptides. 137, 3, p. 168-72 5 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Published

    The ethanol augmentation of glucose-induced insulin secretion is abolished by calcium antagonism with nifedipine: No evidence for a role of glucagon-like peptide-1 (GLP-1)

    Svartberg, J., Holst, Jens Juul, Gutniak, M. K. & Adner, N., 1998, In: Pancreas. 16, p. 66-71

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Published

    The exaggerated glucagon-like peptide-1 response is important for the improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes

    Jørgensen, N. B., Dirksen, C., Bojsen-Møller, K. N., Jacobsen, S. H., Worm, Dorte, Hansen, D. L., Kristiansen, V. B., Naver, L., Madsbad, Sten & Holst, Jens Juul, 6 May 2013, In: Diabetes. 62, 9, p. 3044-3052 9 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  6. Published

    The expanding incretin universe: from basic biology to clinical translation

    Drucker, D. J. & Holst, Jens Juul, 2023, In: Diabetologia. 66, p. 1765-1779

    Research output: Contribution to journalReviewResearchpeer-review

  7. Published

    The feedback cycles between glucose, amino acids and lipids and alpha cell secretion and their role in metabolic fatty liver disease

    Winther-Sørensen, Marie, Holst, Jens Juul & Albrechtsen, Nicolai Jacob Wewer, 2023, In: Current Opinion in Lipidology. 34, 1, p. 27-31

    Research output: Contribution to journalReviewResearchpeer-review

  8. Published

    The gastric acid secretagogue gastrin-releasing peptide and the inhibitor oxyntomodulin do not exert their effect directly on the parietal cell in the rat

    Poulsen, Steen Seier & Holst, Jens Juul, 1988, In: Digestion. 40, 3, p. 144-51 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  9. Published

    The glucagon like peptide-2 'axis': Capacity for production and response following intestinal resection or repair of gastroschisis in infants

    Sigalet, D. L., Lam, V., Brindle, M., Boctor, D., Wallace, L., de Heuval, E., Hartmann, Bolette & Holst, Jens Juul, 2018, In: Journal of Pediatric Surgery. 53, 5, p. 898-904

    Research output: Contribution to journalJournal articleResearchpeer-review

  10. Published

    The glucagon receptor antagonist LY2409021 does not affect gastrointestinal-mediated glucose disposal or the incretin effect in individuals with and without type 2 diabetes

    Hædersdal, S., Lund, A., Nielsen-Hannerup, E., Maagensen, H., Forman, Julie Lyng, Holst, Jens Juul, Knop, Filip Krag & Vilsbøll, Tina, 2022, In: European Journal of Endocrinology. 187, 4, p. 507-518 12 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

ID: 4207